163 Capecitabine chemoradiation for stage II B- III B cervical cancer: preliminary phase I results, Mexican Oncology Study Group

Torrecillas, Laura; Ballesteros, D.; Cervantes, Guadalupe; Cortes, P.; Aldaco, F.; Martell, Robert E.; Fernández, Antonio; Ortega, Belén; Rosas, Lina del Mar Herreros; Erazo, A.

doi:10.1016/s1359-6349(03)90196-0

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a broader context, the impact of oral administration and the favorable safety profile are important when considering quality of life. Consistent efficacy data were reported in our study and two previously reported studies including a combined total of Ͼ170 patients [21,27], and results seem to be similar to data reported with cisplatin regimens. A phase III, randomized trial will help to define the role of capecitabine combined with radiotherapy for treatment of locally advanced cervical cancer.…”

Section: Discussionsupporting

confidence: 93%

“…These results appear to be similar to the efficacy achieved with other single agents, such as cisplatin, paclitaxel, irinotecan, or topotecan, with which a median OS time of 6 -8 months has been reported in the same setting [19]. The feasibility and maximum-tolerated dose of capecitabine in combination with radiotherapy was investigated in a phase I study in rectal cancer [20] and later in a phase I study in stage IIB-IIIB cervical cancer [21]. Both studies identified a Monday-to-Friday regimen with capecitabine given at 825 mg/m 2 twice daily (bid).…”

Section: Introductionsupporting

confidence: 72%

“…Treatment was considered inactive if the ORR was Ͻ35%. The 55% cutoff was considered appropriate by clinicians based on data available at the time [21]. Fifty-nine evaluable patients were required to detect a true ORR Ն55% at the 5% significance level with 90% power.…”

Section: Methodsmentioning

confidence: 99%

“…Both studies identified a Monday-to-Friday regimen with capecitabine given at 825 mg/m 2 twice daily (bid). Of note, complete responses (CRs) were observed in 10 of 12 evaluable patients in the phase I cervical cancer study [21].…”

Section: Introductionmentioning

confidence: 99%

“…Our phase II study was initiated to investigate the safety and efficacy of capecitabine-based chemoradiotherapy in stage IIb-IIIb cervical cancer using the Monday-to-Friday regimen established in phase I studies [20,21]. In addition, the tolerability and potential benefit of capecitabine as adjuvant therapy was explored with a commonly used 3-weekly regimen for a maximum of six cycles.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Capecitabine-Based Chemoradiotherapy with Adjuvant Capecitabine for Locally Advanced Squamous Carcinoma of the Uterine Cervix: Phase II Results

et al. 2009

View full text Add to dashboard Cite

Objectives. Cisplatin-based chemoradiotherapy is the standard treatment for locally advanced cervical cancer but causes considerable toxicity. Capecitabine and radiotherapy show preclinical synergy and clinical activity. The activity, tolerability, and oral administration of capecitabine make it an attractive adjunctive therapy.Methods. In this phase II study, patients with untreated International Federation of Gynecology and Obstetrics stage IIB-IIIB cervical cancer received capecitabine, 825 mg/m 2 twice daily (Monday-Friday), during radiation (45 Gy per 25 fractions external-beam radiotherapy and 26 Gy high-dose rate brachytherapy to point A, maximum 8 weeks), followed by six cycles of capecitabine, 1,000 mg/m 2 twice daily (days 1-14 every 21 days).Results. The overall response rate in 60 patients was 88% (95% confidence interval [CI], 77.4%-95.2%), including complete responses (CRs) in 80% of patients. The 1-year progression-free and overall survival rates were 86% (95% CI, 77%-95%) and 95% (95% CI, 89%-100%), respectively. At 23 months, 76% of patients were progression free (95% CI, 65%-88%) and CR was maintained in 90% (95% CI, 81%-99%) of the 48 patients achieving a CR. There were three grade 3 or 4

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionsupporting

confidence: 72%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Capecitabine-Based Chemoradiotherapy with Adjuvant Capecitabine for Locally Advanced Squamous Carcinoma of the Uterine Cervix: Phase II Results

et al. 2009

View full text Add to dashboard Cite

show abstract

Radiosensitizers in cervical cancer. Cisplatin and beyond

et al. 2006

View full text Add to dashboard Cite

Cervical cancer continues to be a significant health burden worldwide. Globally, the majority of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently used therapeutical modality. Currently, the value of adding cisplatin or cisplatin-based chemotherapy to radiation for treatment of locally advanced cervical cancer is strongly supported by randomized studies and meta-analyses. Nevertheless, despite these significant achievements, therapeutic results are far from optimal; thus, novel therapies need to be assayed. A strategy currently being investigated is the use of newer radiosensitizers alone or in combination with platinum compounds. In the present work, we present preclinical information on known and newer cytotoxic agents as radiosensitizers on cervical cancer models, as well as the clinical information emanating from early phase trials that incorporate them to the cervical cancer management. In addition, we present the perspectives on the combined approach of radiation therapy and molecular target-based drugs with proven radiosensitizing capacity.

show abstract

163 Capecitabine chemoradiation for stage II B- III B cervical cancer: preliminary phase I results, Mexican Oncology Study Group

Cited by 2 publications

References 0 publications

Capecitabine-Based Chemoradiotherapy with Adjuvant Capecitabine for Locally Advanced Squamous Carcinoma of the Uterine Cervix: Phase II Results

Capecitabine-Based Chemoradiotherapy with Adjuvant Capecitabine for Locally Advanced Squamous Carcinoma of the Uterine Cervix: Phase II Results

Radiosensitizers in cervical cancer. Cisplatin and beyond

Contact Info

Product

Resources

About